Berlin, 19 September 2017 – Medios AG, one of the leading competence partners and solutions providers for specialty pharmaceuticals in Germany, has successfully placed new shares with institutional investors. The proceeds from the capital increase amounting to approximately EUR 15.3 Mio. are to be used for further finance growth.
Matthias Gärtner, CFO of Medios AG: „We are pleased about the high demand from the investors. With the funds from the capital increase, we will consistently continue our dynamic growth course, especially by the further expansion of our production capacities in the field of patient-specific preparations.“
In the context of the capital increase from authorized capital, a total number of 1,242,183 shares will be issued and hence the share capital increased by 10 percent to EUR 13,664,019.00. The shares were sold to institutional investors in an accelerated bookbuilding process at a placement price of EUR 12.30 per share. Thereby, the capital increase was covered more than twice.
The issue proceeds will be used to finance the company’s growth strategy, to advance the digitization of the specialty pharma trade business and to enable the further expansion of the customer network and the product range. The capital increase is also intended to further strengthen the company’s capital base.
The new shares are entitled to dividends for the 2017 financial year. They shall be admitted to trading without a prospectus on the Regulated Market of the stock exchanges in Frankfurt and Hamburg-Hannover. The delivery and settlement of the new shares are expected to take place on 22 September 2017.
M.M.Warburg acted as Sole Lead Manager and Sole Bookrunner for the transaction.
Medios is one of the leading competence partners and solutions providers for specialty pharmaceuticals in Germany. These are medicines for patients with rare or chronic diseases such as cancer, HIV and hepatitis, whose personalized therapy is often tedious and cost-intensive due to their individual requirements.
With our subsidiaries Medios Pharma, Medios Manufaktur and Medios Digital we connect individual market players to form cooperating partners. Our goal is to provide partners and customers with integrated solutions along the value chain, ensuring optimal patient care.
Medios AG is Germany’s first listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.
Kirchhoff Consult AG
Telephone: +49 40 60918618
Fax: +49 40 60918660
This publication may not be published, distributed or transmitted, directly or indirectly, in the United States of America (including its territories and possessions), Canada, Japan or Australia or any other jurisdiction where such an announcement could be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons who are in possession of this document or other information referred to herein should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.
This publication does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of Medios AG in the United States of America, Germany or any other juris-diction. In connection with this transaction there has not been nor will there be a public offering and no publication of a securities prospectus.
Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. The securities referred to herein may not be offered or sold in the United States of America in the absence of registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”). The securities of Medios AG have not been, and will not be, registered under the Securities Act.
This announcement does not constitute a recommendation concerning the placement of securities described in this announcement. Investors should consult a professional advisor as to the suitability of the Placement for the person concerned.
In the United Kingdom, this document is only directed at persons who (i)are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended)(the “Order”) or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.)(all such persons together being referred to as “Relevant Persons”). This document must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.
In member states of the European Economic Area which have implemented the Prospectus Directive (each, a “Relevant Member State”), this announcement and any offer, if made subsequently, is directed exclusively at persons who are “qualified investors” within the meaning of the Prospectus Directive. For these purposes, the expression “Prospectus Directive” means Directive 2003/71/EC (and amendments thereto, including the Directive 2010/73/EU), and includes any relevant implementing measure in the Relevant Member State.
No action has been taken that would permit an offering of the securities, a purchase of the securities or possession or distribution of this announcement in any jurisdiction where action for that purpose is required. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions.